Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases. The ADMA news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow developments affecting the ADMA stock and its underlying business.
In its press releases, ADMA regularly reports on quarterly and annual financial results, including total revenue, GAAP net income, adjusted EBITDA and adjusted net income, as well as updates to its financial guidance. The company also issues news on operational milestones such as U.S. Food and Drug Administration (FDA) approvals for its production processes, progress with its yield enhancement production technology, and expansion of its U.S.-based manufacturing and plasma collection infrastructure.
Investors following ADMA news can expect coverage of commercial trends for its FDA-approved plasma-derived products ASCENIV, BIVIGAM and NABI-HB, including reported demand dynamics, payer coverage discussions, and distribution agreements. The company’s updates also address pipeline progress for SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae, along with commentary on intellectual property, supply chain strategy and capital structure actions such as debt refinancing and share repurchase authorizations.
This news page is useful for tracking how ADMA communicates its financial outlook, operational initiatives and product performance over time. Readers interested in the ADMA stock can use the curated news flow to monitor earnings releases, regulatory and manufacturing updates, and other disclosures that the company furnishes through press releases and related filings.
ADMA Biologics has expanded its commercial offering of Immune Globulin (IG) products by introducing additional vial sizes of BIVIGAM and NABI-HB, now available to U.S. healthcare providers.
These new sizes aim to enhance treatment flexibility, reduce drug wastage, and align with competitor offerings. The FDA has approved the 100 mL BIVIGAM vial, complementing the existing 50 mL option. ADMA anticipates that this broader range of vial configurations will facilitate targeted dosing and improve patient care.
ADMA Biologics, a biopharmaceutical company specializing in plasma-derived biologics, will announce its second-quarter financial results on August 11, 2021, after market close. A conference call will follow at 4:30 p.m. ET for discussion of the results and company updates. ADMA's products include ASCENIV™, BIVIGAM®, and NABI-HB®, all FDA-approved for treating immunodeficient patients. The company’s manufacturing is based in Boca Raton, Florida, and it operates FDA-approved plasma collection centers to support its production.
ADMA Biologics announced successful completion of a Pre-Approval Inspection by the FDA for its VanRx fill-finish machine at its Boca Raton facility, with zero observations noted. The company anticipates regulatory approval in the second half of 2021. This approval is expected to enhance internal production capabilities, improve gross margins, and create new revenue opportunities through third-party contracts. ADMA emphasizes its commitment to compliance with Good Manufacturing Practices amidst pandemic-related challenges.
ADMA Biologics, a biopharmaceutical company focused on specialty plasma-derived biologics, announced that CEO Adam Grossman will participate in a fireside chat at the Raymond James Human Health Innovation Virtual Conference on June 21, 2021, at 9:20 a.m. ET. The event will be available via webcast on the company's website and will be archived for 90 days. ADMA manufactures several FDA-approved products aimed at treating immunodeficient patients and operates an FDA-licensed plasma fractionation facility in Boca Raton, Florida.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. ET. The event will be accessible via a webcast on ADMA's website and will be archived for 90 days. ADMA is committed to developing specialty plasma-derived biologics for immunodeficient patients and currently offers three FDA-approved products: BIVIGAM®, ASCENIV™, and NABI-HB®. The company operates an FDA-licensed facility in Boca Raton, Florida, focusing on plasma fractionation and purification.
ADMA Biologics reported first-quarter 2021 revenues of $16.0 million, up 57% from $10.2 million in Q1 2020. The company increased total asset value to $235.7 million, including $94.1 million in inventories, aimed at supporting production growth in a supply-constrained IVIG market. ADMA narrowed net losses to $18.4 million or $(0.16) per share, an improvement from $(19.2 million) or $(0.26) per share last year. The FDA's approval for IVIG production scale expansion is expected to boost capacity by 50%.
ADMA Biologics will announce its financial results for Q1 2021 on May 12, 2021, after market close. The event will include a conference call at 4:30 p.m. ET to discuss financial performance and company updates. ADMA specializes in plasma-derived biologics for immunodeficient patients, holding FDA approvals for three products: ASCENIV™, BIVIGAM®, and NABI-HB®. The call can be accessed via phone or audio webcast, with availability for an archived recording soon after.
ADMA Biologics announces a significant expansion in manufacturing capacity, increasing from 400,000 liters to 600,000 liters, enhancing its potential peak revenues to exceed $300 million. The FDA has approved the company’s expanded manufacturing process for intravenous immune globulin (IVIG), which is expected to enhance gross margins and operational efficiencies starting late 2021 and throughout 2022. This expansion allows ADMA to produce IVIG using a 4,400-liter plasma pool, confirming its position in the market and paving the way for consistent revenue growth.
ADMA Biologics, Inc. (NASDAQ: ADMA) announced the opening of its new plasma collection facility in Goose Creek, South Carolina, marking a significant expansion in its operations. Governor Henry McMaster participated in the ribbon-cutting ceremony, highlighting South Carolina's favorable environment for plasma collection. ADMA aims to have 10 or more facilities operational by 2024 to meet growing plasma demand. The new facility will enhance ADMA's self-sufficient plasma supply chain and support revenue growth. A Biologics License Application (BLA) is expected to be filed in three months.
ADMA Biologics presented a poster at the 2021 Academy of Managed Care Pharmacy Annual Meeting, emphasizing the substantial healthcare costs associated with Hepatitis B Virus (HBV) and its higher transmission risk compared to HIV. The analysis advocates for aligning CDC treatment guidelines for sexual assault victims exposed to HBV with those for HIV. The proposed intervention involves using Nabi-HB, a hyperimmune globulin, to provide cost-effective prophylaxis. CEO Adam Grossman urges policymakers to address this unmet patient need to mitigate clinical and financial consequences for the healthcare system.